NCT03762616 is a NA clinical trial of Micro-ultrasound targeted biopsy in Prostate Cancer, sponsored by Exact Imaging.

Who is sponsoring NCT03762616?

NCT03762616 is sponsored by Exact Imaging.

What drugs are being tested in NCT03762616?

Interventions in NCT03762616: Micro-ultrasound targeted biopsy, mpMRI targeted biopsy.

What condition does NCT03762616 study?

NCT03762616 studies Prostate Cancer.

Is NCT03762616 still recruiting?

NCT03762616 is currently completed. Last updated 21 April 2021.

Are results published for NCT03762616?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-04-21 · How we verify

NCT03762616

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urology San Antonio MRI/MicroUS Comparison

Completed NA Results posted Last updated 21 April 2021

What this trial tests

NA trial testing Micro-ultrasound targeted biopsy in Prostate Cancer in 120 participants. Completed in 4 November 2019.

Timeline

28 November 2018

Primary endpoint
4 November 2019

4 November 2019

Quick facts

Lead sponsor	Exact Imaging
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	single
Primary purpose	diagnostic
Enrollment	120
Start date	28 November 2018
Primary completion	4 November 2019
Estimated completion	4 November 2019
Sites	1 location across United States

Drugs / interventions tested

Micro-ultrasound targeted biopsy
mpMRI targeted biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Exact Imaging

Who can join

Adults 40 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Clinically Significant Cancer Primary · At time of biopsy

Comparison of subject-level detection rate of clinically significant cancer (csPCa, defined as Grade Group 2 or higher) between micro-ultrasound targeted biopsy and mpMRI targeted biopsy.

Group	Value	95% CI
Micro-ultrasound Biopsy	38
MRI Targeted Biopsy	31

Sponsor's own description

This study compares micro-ultrasound image targeted prostate biopsy with multi-parametric MRI targeted biopsy in men indicated for prostate biopsy due to suspicion of prostate cancer. Both imaging techniques will be applied to each subject and compared, along with systematic biopsy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review.
Dias AB, O'Brien C, Correas JM, Ghai S. · · 2022 · cited 22× · PMID 34752132 · DOI 10.1259/bjr.20210633

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03762616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exact Imaging
Last refreshed: 21 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing